As per a multicenter observational study of 465 women in Russia published in International Journal of Gynaecology & Obstetrics, Triptorelin was found to have a favourable safety profile and efficacy in the treatment of clinical symptoms of adenomyosis and helps to improve the reproductive function.

Adenomyosis, a type of endometriosis is described by benign endometrial invasion into the myometrium. Its symptoms include menstrual illnesses and continuing pain syndrome, thereby affecting the quality of life. The study authors examined the efficacy of triptorelin for adenomyosis treatment in women in Russia.

In females (aged 25-40 years) who were gonadotropin-releasing hormone agonist treatment-naïve and had a diagnosis of endometriosis or adenomyosis with menorrhagia, an intramuscular injection of triptorelin 3.75 mg was utilized every 28 days.

Interviews to examine symptom severity, medical record review, and pelvic evaluations comprising transvaginal ultrasound were carried out. The data was gathered at different visits i.e. at visit 1 (first injection of triptorelin); visit 2 (day of the last injection), visit 3 (6 months after the last injection), and visit 4 (9 months after the last injection).

Out of a total of 465 women, a noteworthy improvement from starting in the severity of menorrhagia in 390/463 (84.2%) of women at visit 3 was observed. Also, at visit 3, the severity of dysmenorrhea, abnormal uterine bleeding (AUB), and pelvic pain were decreased (Figure 1- a and b):

Figure 1- a and b: Proportion of women with dysmenorrhea and pelvic pain during triptorelin therapy, characterized by endometriosis stage (effectiveness set).

At visit 2 and visit 3, the symptoms of endometriosis stopped in 96.6% of women at and 92.4% of women, respectively. No serious adverse events were reported.